Publications by authors named "S Piergallini"
Background: Data regarding the real-world (RW) use of tofacitinib (TOF) in patients with ulcerative colitis (UC) are limited. We aimed to investigate TOF's RW efficacy and safety in Italian UC patients.
Research Design And Methods: A retrospective assessment of clinical and endoscopic activity was performed according to the Mayo score.
Background: The SARS-COV 2 pandemic has hit on our lives since early 2020. During different contagion waves, both malnutrition and overweight significantly correlated with patient mortality. Immune-nutrition (IN) has shown promising results in the clinical course of pediatric inflammatory bowel disease (IBD) and in both the rate of extubation and mortality of patients admitted to an intensive care unit (ICU).
View Article and Find Full Text PDFBackground: Vedolizumab (VDZ) can be used to treat refractory ulcerative colitis (UC) and Crohn's disease (CD). We assessed whether there are differences in treating UC vs CD with VDZ.
Research Design And Methods: Mayo score in UC and the Harvey-Bradshaw Index (HBI) in CD scored the clinical activity.
Article Synopsis
- Infliximab and adalimumab are both commonly used medications for treating Crohn's disease and ulcerative colitis, and this study aimed to evaluate their long-term effectiveness and safety in real-life clinical settings.
- A total of 712 patients were reviewed, showing that both treatments maintained clinical remission similarly in Crohn's disease, but infliximab showed better results for ulcerative colitis.
- Adalimumab had a significantly lower rate of adverse events compared to infliximab, making it a potentially safer option for patients.
Objective: Ustekinumab (UST) is an anti-IL12/23 antibody for the treatment of Crohn's Disease (CD). The aim of this study was to compare the efficacy and safety of UST in a large population-based cohort of CD patients who failed previous treatment with other biologics.
Patients And Methods: 194 CD patients (108 males and 86 females, mean age 48 years (range 38-58 years) were retrospectively reviewed.